MarketBeat
22 Nov 2026, 19:12 UTC · 2h ago
Ocular Therapeutix Targets Q4 FDA Filing for AXPAXLI After Key Trial Win
Impact · against what's priced in
OCUL is positioned for a near-term catalyst with a Q4 FDA submission for AXPAXLI, supported by high-confidence Phase 3 SOL-1 data. The strategic adjustments to the SOL-R trial and the 2027 horizon for diabetic retinal disease provide a clear roadmap for regulatory and commercial expansion.
- OCUL+0.70
No priced-in read yet
- In context
The company is on track for a Q4 FDA submission for AXPAXLI based on SOL-1 trial data (p < 0.0006), meeting the FDA's threshold for single-trial submissions. Additional value is created by moving the SOL-R endpoint to week 40 to mitigate operational bias and extending unmasking to week 96 to avoid review cycle amendments.
Read from the article alone

Search tags




